002826.SHE Tibet Aim Pharm Inc
- Market cap
- CNY 2.82B
- P/E
- 24.6x
- P/B
- 3.29x
- ROE
- 15.7%
- Dividend yield
- 0.85%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002826.SHE undervalued?
Graham number002826.SHE trades 89.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tibet Aim Pharm Inc fundamental analysis
No fundamental analysis for Tibet Aim Pharm Inc yet.
Tibet Aim Pharm Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tibet Aim Pharm Inc
Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company's products include Miglitol tablets for diabetes; ethnic medicine products, suitable for treating breast lobular hyperplasia, uterine fibroids, and ovarian cysts; medicines for gynecology and obstetrics; and Gualoupi injection, Nalmefene hydrochloride injection, and Carbetocin injection. It also provides Domperidone tablets for treatment of indiges…
Full company profileTibet Aim Pharm Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tibet Aim Pharm Inc annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 452M | 380M | 489M | 553M | 603M | 725M | 857M | 667M | 652M | 636M | 749M |
| Gross Profit | 319M | 271M | 156M | 182M | 217M | 261M | 376M | 341M | 446M | 522M | 615M |
| Operating Income | 47.2M | 65.1M | 26.9M | 47.7M | 43.1M | 48.6M | 55.7M | 23.5M | 61.5M | 98.6M | 164M |
| EBITDA | 75.6M | 76.8M | 39.9M | 61.4M | 65.8M | 74.5M | 80.2M | 48.9M | 82.4M | 134M | 165M |
| Net Income | 55.4M | 60.5M | 25.3M | 37.3M | 41.1M | 42.5M | 44.1M | 15.4M | 45.9M | 92.6M | 132M |
| EPS | 0.38 | 0.32 | 0.13 | 0.20 | 0.22 | 0.22 | 0.23 | 0.08 | 0.25 | 0.49 | 0.69 |
| Balance Sheet | |||||||||||
| Total Assets | 646M | 733M | 758M | 835M | 908M | 824M | 1.02B | 928M | 926M | 1.02B | 1.23B |
| Total Liabilities | 90.9M | 129M | 140M | 183M | 221M | 104M | 268M | 178M | 181M | 202M | 388M |
| Shareholders' Equity | 555M | 605M | 618M | 652M | 687M | 717M | 745M | 745M | 739M | 816M | 845M |
| Cash & Short-term Investments | 281M | 262M | 239M | 190M | 205M | 183M | 321M | 386M | 427M | 538M | 424M |
| Total Debt | 10.0M | - | 40.0M | 70.0M | 40.0M | 6.65M | 50.1M | 11.0M | 22.8M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 57.2M | 77.3M | 13.3M | 59.2M | 102M | 110M | 68.5M | 167M | 112M | 124M | - |
| Capital Expenditure | 18.5M | 74.6M | 67.7M | 170M | 38.4M | 25.2M | 3.20M | 3.18M | 12.2M | 8.50M | 5.27M |
| Free Cash Flow | 38.7M | 2.67M | -54.4M | -111M | 63.3M | 84.3M | 65.3M | 164M | 99.3M | 115M | 311M |
| Ratios | |||||||||||
| ROE | 10.0% | 10.0% | 4.1% | 5.7% | 6.0% | 5.9% | 5.9% | 2.1% | 6.2% | 11.3% | 15.7% |
| ROA | 8.6% | 8.2% | 3.3% | 4.5% | 4.5% | 5.2% | 4.3% | 1.7% | 5.0% | 9.1% | 10.7% |
| Net Profit Margin | 12.2% | 15.9% | 5.2% | 6.7% | 6.8% | 5.9% | 5.2% | 2.3% | 7.0% | 14.6% | 17.7% |
| Debt to Equity | 0.02x | - | 0.06x | 0.11x | 0.06x | 0.01x | 0.07x | 0.01x | 0.03x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tibet Aim Pharm Inc dividends
- Dividend yield
- 0.85%
- Forward dividend
- 0.15 CNY
- Payout ratio
- 25.8%
- Ex-dividend date
- Jun 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 23.8M | 0.13 | 25.8% |
| 2024 | CNY 6.04M | 0.03 | 13.1% |
| 2023 | CNY 20.3M | 0.11 | 131.8% |
| 2022 | CNY 19.0M | 0.10 | 43.1% |
| 2021 | CNY 15.3M | 0.08 | 36.0% |
| 2020 | CNY 7.67M | 0.04 | 18.7% |
| 2019 | CNY 5.69M | 0.03 | 15.2% |
| 2018 | CNY 12.8M | 0.07 | 50.5% |
| 2017 | CNY 11.4M | 0.06 | 18.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Tibet Aim Pharm Inc
- Insiders 37.43%
- Institutions 1.82%
- Public & others 60.75%
- Shares outstanding 191M
- Free float 127M
Tibet Aim Pharm Inc company profile
- Company name
- Tibet Aim Pharm Inc
- Ticker
- 002826.SHE
- ISIN
- CNE100002C39
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 405
- Fiscal year end
- December
- Address
- No. 6, Linqionggang Road, Lhasa, China, 850000
- Phone
- 86 10 5873 1208
- Website
- emyy.cn
About Tibet Aim Pharm Inc
Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company's products include Miglitol tablets for diabetes; ethnic medicine products, suitable for treating breast lobular hyperplasia, uterine fibroids, and ovarian cysts; medicines for gynecology and obstetrics; and Gualoupi injection, Nalmefene hydrochloride injection, and Carbetocin injection. It also provides Domperidone tablets for treatment of indigestion, abdominal bloating, belching, nausea, vomiting, and abdominal distension and pain; Montmorillonite powder for chronic diarrhea; and Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, as well as for the treatment of antibiotics, antiallergic, and digestive systems. Tibet AIM Pharm. Inc. was founded in 2003 and is based in Lhasa, China.
Tibet Aim Pharm Inc management
2- Mr. Ke XuGM & CFO · born 1978
- Ms. Qianjin LiSecretary of the Board of Directors · born 1977